Skip to main content
. 2016 Nov 15;4:72. doi: 10.1186/s40425-016-0177-2

Fig. 3.

Fig. 3

Peripheral a PD-1 occupancy and b receptor occupancy (RO) of patients treated with nivolumab. MEL = melanoma; PD-1 = programmed death–1; pts = patients